Heparanase‐Expressing Regulatory T Cells Drive Immunotherapy Resistance and Poor Outcomes in Lung Cancer
International Journal of Cancer · 18.11.2026
DOI: 10.1002/ijc.70824 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 18.11.2026. Verfasst von Ryohiko Ozaki und 15 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
Heparan sulfate proteoglycans (HSPGs) and their degrading enzyme heparanase (Hpse) play pivotal roles in tumor invasion and metastasis. Previous studies have reported associations between Hpse expression in tumor cells and patient prognosis. Although immune checkpoint inhibitors (ICIs) are a cornerstone of solid tumor therapy, the role of Hpse in antitumor immunity remains unclear. Here, we examined Hpse localization and its impact on the immune microenvironment in lung adenocarcinoma. To investigate the relationships among the Hpse expression, tumor prognosis, and tumor‐infiltration of immune cells, an immunohistochemical analysis of Hpse1, Hpse2, regulatory T cells (T reg s), macrophages, and CD8 + T cells was performed in resected tumor tissue from lung adenocarcinoma patients. The effects of the Hpse inhibitor PG545 on the invasive capabilities of lymphocytes were investigated. In lung adenocarcinoma tissues, Hpse1 and Hpse2 were expressed in both epithelial tumor cells and immune cells. A high Hpse1 expression and low Hpse2 expression are poor postoperative prognostic factors in both epithelial cells and tumor‐infiltrating hematopoietic cells. Single‐cell RNA sequencing of human tumor‐infiltrating immune cells revealed that T reg s and some subclusters of macrophages specifically express Hpse1. Lung adenocarcinoma tissue with high Hpse‐expressing immune cells demonstrated an increase in tumor‐infiltrating T reg s. PG545 suppressed the invasion of T reg s toward the HSPG‐containing ECM. Furthermore, PG545 suppressed tumor progression and infiltration of T reg s in a mouse model. In addition, PG545 reinforced antitumor effects of PD‐L1 blockade. Hpse expression in T reg s has a significant impact on lung cancer progression and is a promising therapeutic target for novel combination immunotherapy.
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Ozaki, R., Mitsuhashi, A., Ogino, H., Yoshida, A., Koyama, K., Yabuki, Y., Tsukazaki, Y., Morita, Y., Sato, S., Nokihara, H., Shinohara, T., Hanibuchi, M., Takizawa, H., Ilan, N., Vlodavsky, I., & Nishioka, Y. (2026). Heparanase‐Expressing Regulatory T Cells Drive Immunotherapy Resistance and Poor Outcomes in Lung Cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70824
Vancouver
Ozaki R, Mitsuhashi A, Ogino H, Yoshida A, Koyama K, Yabuki Y, et al. Heparanase‐Expressing Regulatory T Cells Drive Immunotherapy Resistance and Poor Outcomes in Lung Cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70824
BibTeX
@article{Ozaki2026,
author = {Ozaki, Ryohiko and Mitsuhashi, Atsushi and Ogino, Hirokazu and Yoshida, Aito and Koyama, Kazuya and Yabuki, Yohei and Tsukazaki, Yuki and Morita, Yutaka and Sato, Seidai and Nokihara, Hiroshi and Shinohara, Tsutomu and Hanibuchi, Masaki and Takizawa, Hiromitsu and Ilan, Neta and Vlodavsky, Israel and Nishioka, Yasuhiko},
title = {Heparanase‐Expressing Regulatory T Cells Drive Immunotherapy Resistance and Poor Outcomes in Lung Cancer},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70824}
}
EUVIMED